Clinical Trial

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Name: Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis — clinical trial record (NCT06833112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.

Trial Details

NCT Number	NCT06833112
Lead Sponsor	The Affiliated Hospital Of Guizhou Medical University
Conditions	Ankylosing Spondylitis
Enrollment	10 participants
Start Date	2025-02
Primary Completion	2027-08 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2025-02-18